Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Reports Positive Results for PD-1 Candidate; Files China NDA

publication date: May 17, 2018

Innovent Biologics of Suzhou reported strong preliminary results from a China Phase II trial of its PD-1 candidate, sintilimab (IBI308). In 96 patients with relapsed/refractory classical Hodgkin Lymphoma, sintilimab produced an overall response rate of 79% and a disease control rate of 98%, meeting the endpoints of the study. Innovent said it submitted an NDA to the CFDA for sintilimab on April 19, 2018, which will be reviewed following speeded-up Priority Review rules. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital